Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center to advance preclinical studies of its WEE1 kinase inhibitor, APR-1051. …
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research Read More